Monjuvi brings targeted lymphoma treatment option to US adults

Monjuvi offers a targeted option for adults with relapsed or refractory diffuse large B-cell lymphoma in the United States, used together with lenalidomide under FDA-approved conditions of use.

Monjuvi is a prescription CD19-directed monoclonal antibody for adults with certain diffuse large B-cell lymphoma in the United States, used in combination with lenalidomide under specific FDA-approved conditions of use.

As of: 06/06/2026 | Reading time: approx. 9 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Monjuvi
• Category: CD19-directed monoclonal antibody for lymphoma
• Brand/Manufacturer: Incyte and MorphoSys
• Primary Use Cases: Adult patients with certain relapsed or refractory diffuse large B-cell lymphoma
• Availability: Prescription only, marketed in the United States
• Core Markets: Oncology centers and hospitals treating aggressive B-cell lymphomas

What Monjuvi Is and How It Works

Monjuvi is the brand name for tafasitamab-cxix, a humanized monoclonal antibody that targets the CD19 antigen on B cells, including malignant B cells found in diffuse large B-cell lymphoma. It is administered by intravenous infusion and is used only under specialist supervision.

This therapy is indicated for adult patients with certain forms of relapsed or refractory diffuse large B-cell lymphoma who are not candidates for intensive curative treatments such as autologous stem cell transplantation. In clinical practice, it is typically given together with lenalidomide followed by Monjuvi as a single agent.

The way Monjuvi works is based on recognizing CD19 on the surface of B cells and helping the immune system attack and destroy these malignant cells. As an antibody therapy, it does not function like traditional chemotherapy; instead, it relies on immune-mediated mechanisms guided by the CD19 target.

Monjuvi is given on a defined treatment schedule, particularly intensive during the initial cycles when combined with lenalidomide. Dosing and timing are individualized by oncology teams, taking into account factors such as the patient’s overall health, prior therapies, and tolerability.

Because Monjuvi is an intravenous medicine, infusions are provided in oncology clinics or hospital infusion centers. Premedication and monitoring are commonly used to reduce the risk of infusion-related reactions and to ensure patient safety during administration.

Why Monjuvi Matters for US Consumers and Industry

In the United States, diffuse large B-cell lymphoma is one of the most common aggressive non-Hodgkin lymphomas, and many patients experience disease that returns or does not respond to initial therapy. For adults who are not candidates for intensive options, access to additional targeted treatments can be clinically important.

Monjuvi provides a treatment option that can be used in appropriate adult patients whose disease has relapsed or is refractory, particularly when other options are limited. It is intended for use by hematology and oncology specialists who can evaluate whether the benefit-risk balance is suitable for an individual patient’s condition.

From an industry perspective, Monjuvi illustrates the continued shift toward targeted and antibody-based therapies in hematologic malignancies. The product’s focus on CD19 adds to the broader therapeutic toolbox available in the US market for B-cell lymphomas, alongside chemotherapy, other antibodies, and cellular therapies.

For US patients and caregivers, the availability of a non-chemotherapy antibody option that is used in combination with an oral agent may offer a different treatment approach compared with traditional regimens. Discussion with healthcare professionals is essential to understand how Monjuvi fits alongside other available treatments.

Insurers and healthcare systems in the United States generally evaluate such therapies within their oncology benefit structures. Coverage policies, prior authorization requirements, and patient support programs can all affect how readily patients can access Monjuvi through their treating centers.

Monjuvi in the US and Global Market

Monjuvi is co-commercialized in the United States by Incyte and MorphoSys, reflecting a partnership strategy that combines development expertise with commercial infrastructure. The product is positioned specifically in hematology-oncology, focusing on a defined patient segment rather than broad-line oncology use.

Within the US market, Monjuvi competes with other therapies for relapsed or refractory diffuse large B-cell lymphoma, including antibody-based regimens and cellular therapies. Each option has different eligibility criteria, administration requirements, and safety considerations, which physicians weigh case by case.

Globally, tafasitamab-based therapies may be marketed under regional brand strategies and regulatory frameworks, but in the United States the Monjuvi brand and its approved indication are the central focus. US oncology centers frequently evaluate such therapies through tumor boards and multidisciplinary teams.

Supply and distribution of Monjuvi in the United States typically occur through specialty pharmacies and hospital purchasing channels. This reflects the medicine’s status as a specialist oncology treatment administered in a controlled healthcare environment rather than in retail pharmacy settings.

As part of the evolving treatment landscape for diffuse large B-cell lymphoma, Monjuvi contributes to a more diversified set of options that can be matched to patient needs, prior treatment history, and institutional capabilities. Its role may continue to be defined by ongoing clinical experience and evolving treatment guidelines.

• CD19-directed monoclonal antibody for adult B-cell lymphoma
• Intravenous infusion given in oncology centers
• Used with lenalidomide in specified relapsed or refractory cases
• Developed through partnership between MorphoSys and Incyte
• Available to US patients via specialist prescription only

Frequently Asked Questions About Monjuvi

Who can receive Monjuvi?
Monjuvi is used for certain adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for some intensive curative treatments. Eligibility is determined by a hematologist or oncologist.

How is Monjuvi given?
Monjuvi is administered as an intravenous infusion on a defined schedule, usually initially in combination with lenalidomide. The infusion takes place in a clinic or hospital under the supervision of trained healthcare professionals.

Is Monjuvi a chemotherapy?
Monjuvi is not a traditional chemotherapy. It is an antibody that targets CD19 on B cells and relies on immune mechanisms to help destroy malignant cells. It is still a potent cancer medicine and requires close monitoring.

MorphoSys is the biopharmaceutical company closely associated with the development of Monjuvi, particularly through its research into antibody therapies for cancer and other serious diseases in collaboration with partners.

Shares of MorphoSys are associated with the ISIN DE0006632003 and are used purely as a financial identifier for the issuing company behind Monjuvi, separate from the clinical and patient-focused role of the medicine itself.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.